首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Genetic Basis for Vancomycin-Enhanced Cephalosporin Susceptibility in Vancomycin-Resistant Enterococci Revealed Using Counterselection with Dominant-Negative Thymidylate Synthase
【2h】

Genetic Basis for Vancomycin-Enhanced Cephalosporin Susceptibility in Vancomycin-Resistant Enterococci Revealed Using Counterselection with Dominant-Negative Thymidylate Synthase

机译:使用显性负胸苷酸合酶的反选择揭示了万古霉素增强的头孢菌素敏感性在万古霉素抗性肠球菌中的遗传基础。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Antibiotic-resistant enterococci are major causes of hospital-acquired infections. All enterococci are intrinsically resistant to most cephalosporins, antibiotics in the beta-lactam family that impair peptidoglycan synthesis by inactivating the transpeptidases responsible for cross-linking. In addition, clinical isolates of enterococci often possess acquired resistance to vancomycin, a glycopeptide antibiotic that impairs peptidoglycan biosynthesis by a mechanism distinct from that of the beta-lactams, namely, by binding to the d-Ala-d-Ala termini found in peptidoglycan precursors to prevent their utilization by biosynthetic transglycosylases. Antimicrobial synergism between vancomycin and beta-lactams against vancomycin-resistant enterococci was originally described decades ago, but the genetic basis for synergy has remained unknown. Because a complete understanding of the mechanism underlying synergy between vancomycin and beta-lactams might suggest new targets or strategies for therapeutic intervention against antibiotic-resistant enterococci, we explored the genetic basis for synergy between vancomycin and cephalosporins in Enterococcus faecalis. To do so, we developed a counterselection strategy based on a dominant-negative mutant of thymidylate synthase and implemented this approach to create a panel of mutants in vancomycin-resistant E. faecalis. Our results confirm that vancomycin promotes synergy by inducing expression of the van resistance genes, as a mutant in which the van genes are expressed in the absence of vancomycin exhibits susceptibility to cephalosporins. Further, we show that peptidoglycan precursors substituted with d-Ala-d-Lac are not required for vancomycin-enhanced cephalosporin sensitivity. Instead, production of the d,d-carboxypeptidase VanYB is both necessary and sufficient to dramatically sensitize E. faecalis to cephalosporins.
机译:抗生素耐药的肠球菌是医院获得性感染的主要原因。所有肠球菌都对大多数头孢菌素具有内在抗性,β-内酰胺家族中的大多数抗生素通过使负责交联的转肽酶失活而破坏肽聚糖的合成。此外,肠球菌的临床分离株通常对万古霉素具有获得性抗药性,万古霉素是一种通过与β-内酰胺不同的机制,即通过与在肽聚糖中发现的d-Ala-d-Ala末端结合而损害肽聚糖生物合成的糖肽抗生素。前体以防止被生物合成的转糖基化酶利用。万古霉素和β-内酰胺类药物对耐万古霉素的肠球菌的抗菌协同作用最初是在几十年前描述的,但是协同作用的遗传基础仍然未知。因为对万古霉素和β-内酰胺协同作用的潜在机制有一个完整的了解,可能提出针对抗生素耐药性肠球菌的新治疗靶标或治疗干预策略,所以我们探索了粪肠球菌中万古霉素与头孢菌素之间协同作用的遗传基础。为此,我们开发了基于胸苷酸合酶显性阴性突变体的反选择策略,并实施了该方法以在耐万古霉素的粪肠球菌中创建一组突变体。我们的结果证实,万古霉素通过诱导van抗性基因的表达来促进协同作用,因为在不存在万古霉素的情况下表达van基因的突变体表现出对头孢菌素的敏感性。此外,我们显示万古霉素增强的头孢菌素敏感性不需要用d-Ala-d-Lac取代的肽聚糖前体。取而代之的是,d,d-羧肽酶VanYB的产生对于使粪肠球菌对头孢菌素显着敏感是必要的和充分的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号